Gilead Sciences, Inc. is downgraded to Hold due to uncertainty on the Arcellx acquisition and cell therapy portfolio challenges. Read more on GILD stock here.
With Combine Week underway, Daniel Jeremiah updates his prospect rankings for the 2026 NFL Draft. Three new players make the list, and a tight end is among the biggest risers. Check out the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results